Table 4

Adverse events in treatment and control groups

Treatment group, n (%)
(N = 30 )Control group, n (%)
(N = 24)P value*
Abdominal pain1 (3.3)0 (0.0)1.000
Back pain0 (0.0)1 (4.2)0.444
Blood pressure increased1 (3.3)0 (0.0)1.000
Cardiac arrest1 (3.3)0 (0.0)1.000
Cellulitis0 (0.0)2 (8.3)0.193
Constipation0 (0.0)1 (4.2)0.444
C-reactive protein increased0 (0.0)1 (4.2)0.444
Diabetes inadequate control1 (3.3)0 (0.0)1.000
Diabetic neuropathy1 (3.3)0 (0.0)1.000
Dizziness1 (3.3)0 (0.0)1.000
Dyspnea1 (3.3)0 (0.0)1.000
Hyperglycemia1 (3.3)2 (8.3)0.579
Hyperkalemia0 (0.0)1 (4.2)0.444
Nasopharyngitis0 (0.0)1 (4.2)0.444
Nephropathy0 (0.0)1 (4.2)0.444
Edema1 (3.3)0 (0.0)1.000
Osteoporosis1 (3.3)0 (0.0)1.000
Pain in extremity2 (6.7)1 (4.2)1.000
Paresthesia1 (3.3)2 (8.3)0.579
Pleural effusion0 (0.0)1 (4.2)0.444
Proteinuria1 (3.3)0 (0.0)1.000
Pyelonephritis acute1 (3.3)0 (0.0)1.000
Pyrexia0 (0.0)1 (4.2)0.444
Trigger finger1 (3.3)0 (0.0)1.000
  • *Fisher exact test.